_id
69104e3eccc777a4e85d532b
Ticker
CHRS
Name
Coherus BioSciences Inc
Exchange
NASDAQ
Address
333 Twin Dolphin Drive, Redwood City, CA, United States, 94065
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.coherus.com
Description
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Last Close
1.43
Volume
750018
Current Price
1.35
Change
-5.594405594405584
Last Updated
2025-11-29T11:27:05.971Z
Image
-
Ipo Date
2014-11-06T00:00:00.000Z
Market Cap
164384576
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.5125
Sentiment Sources
4
Rating
4
Target Price
5.6667
Strong Buy
3
Buy
1
Hold
3
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
11571000
Cost Of Revenue
3721000
Gross Profit
7850000
Operating Expenses
52183000
Operating Income
-44333000
Interest Expense
2325000
Pretax Income
-44517000
Net Income
-35531000
Eps
-0.3056977865367188
Dividends Per Share
-
Shares Outstanding
120871013
Income Tax Expense
-8986000
EBITDA
-41226000
Operating Margin
-383.13888168697605
Total Other Income Expense Net
-184000
Cash
103352000
Short Term Investments
88311000
Receivables
250496000
Inventories
2048000
Total Current Assets
460955000
Property Plant Equipment
1633000
Total Assets
516519000
Payables
24893000
Short Term Debt
1791000
Long Term Debt
36957000
Total Liabilities
428745000
Equity
87774000
Depreciation
966000
Change In Working Capital
-9389000
Cash From Operations
-46339000
Capital Expenditures
0
Cash From Investing
-67227000
Cash From Financing
2000
Net Change In Cash
-113564000
PE
2.4727
PB
1.7876521464214918
ROE
-40.480096611752906
ROA
-6.878933785591624
FCF
-46339000
Fcf Percent
-4.004753262466511
Piotroski FScore
0
Health Score
16
Deep Value Investing Score
6
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
2.5
Momentum Investing Score
6.5
Net Net Investing Score
2
Quality Investing Score
1.5
Value Investing Score
6
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
11571000
Quarters > 0 > income Statement > cost Of Revenue
3721000
Quarters > 0 > income Statement > gross Profit
7850000
Quarters > 0 > income Statement > operating Expenses
52183000
Quarters > 0 > income Statement > operating Income
-44333000
Quarters > 0 > income Statement > interest Expense
2325000
Quarters > 0 > income Statement > pretax Income
-44517000
Quarters > 0 > income Statement > net Income
-35531000
Quarters > 0 > income Statement > eps
-0.3056977865367188
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
116229170
Quarters > 0 > income Statement > income Tax Expense
-8986000
Quarters > 0 > income Statement > EBITDA
-41226000
Quarters > 0 > income Statement > operating Margin
-383.13888168697605
Quarters > 0 > income Statement > total Other Income Expense Net
-184000
Quarters > 0 > balance Sheet > cash
103352000
Quarters > 0 > balance Sheet > short Term Investments
88311000
Quarters > 0 > balance Sheet > receivables
250496000
Quarters > 0 > balance Sheet > inventories
2048000
Quarters > 0 > balance Sheet > total Current Assets
460955000
Quarters > 0 > balance Sheet > property Plant Equipment
1633000
Quarters > 0 > balance Sheet > total Assets
516519000
Quarters > 0 > balance Sheet > payables
24893000
Quarters > 0 > balance Sheet > short Term Debt
1791000
Quarters > 0 > balance Sheet > long Term Debt
36957000
Quarters > 0 > balance Sheet > total Liabilities
428745000
Quarters > 0 > balance Sheet > equity
87774000
Quarters > 0 > cash Flow > net Income
-35531000
Quarters > 0 > cash Flow > depreciation
966000
Quarters > 0 > cash Flow > change In Working Capital
-9389000
Quarters > 0 > cash Flow > cash From Operations
-46339000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-67227000
Quarters > 0 > cash Flow > cash From Financing
2000
Quarters > 0 > cash Flow > net Change In Cash
-113564000
Quarters > 0 > ratios > PE
-0.3056977865367188
Quarters > 0 > ratios > PB
1.7876521464214918
Quarters > 0 > ratios > ROE
-40.480096611752906
Quarters > 0 > ratios > ROA
-6.878933785591624
Quarters > 0 > ratios > FCF
-46339000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-4.004753262466511
Quarters > 0 > health Score
16
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
10254000
Quarters > 1 > income Statement > cost Of Revenue
3395000
Quarters > 1 > income Statement > gross Profit
6859000
Quarters > 1 > income Statement > operating Expenses
52345000
Quarters > 1 > income Statement > operating Income
-45486000
Quarters > 1 > income Statement > interest Expense
2277000
Quarters > 1 > income Statement > pretax Income
-44862000
Quarters > 1 > income Statement > net Income
297767000
Quarters > 1 > income Statement > eps
2.565238407959633
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
116077710
Quarters > 1 > income Statement > income Tax Expense
-342629000
Quarters > 1 > income Statement > EBITDA
-41569000
Quarters > 1 > income Statement > operating Margin
-443.59274429490927
Quarters > 1 > income Statement > total Other Income Expense Net
624000
Quarters > 1 > balance Sheet > cash
216893000
Quarters > 1 > balance Sheet > short Term Investments
20744000
Quarters > 1 > balance Sheet > receivables
119639000
Quarters > 1 > balance Sheet > inventories
4513000
Quarters > 1 > balance Sheet > total Current Assets
380205000
Quarters > 1 > balance Sheet > property Plant Equipment
1907000
Quarters > 1 > balance Sheet > total Assets
439464000
Quarters > 1 > balance Sheet > payables
37622000
Quarters > 1 > balance Sheet > short Term Debt
1756000
Quarters > 1 > balance Sheet > long Term Debt
36867000
Quarters > 1 > balance Sheet > total Liabilities
319637000
Quarters > 1 > balance Sheet > equity
119827000
Quarters > 1 > cash Flow > net Income
297767000
Quarters > 1 > cash Flow > depreciation
1016000
Quarters > 1 > cash Flow > change In Working Capital
-23652000
Quarters > 1 > cash Flow > cash From Operations
-46632000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
462638000
Quarters > 1 > cash Flow > cash From Financing
-281524000
Quarters > 1 > cash Flow > net Change In Cash
134482000
Quarters > 1 > ratios > PE
2.565238407959633
Quarters > 1 > ratios > PB
1.307759590910229
Quarters > 1 > ratios > ROE
248.49741710966643
Quarters > 1 > ratios > ROA
67.75685835472302
Quarters > 1 > ratios > FCF
-46632000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
-4.547688706846109
Quarters > 1 > health Score
60
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
7599000
Quarters > 2 > income Statement > cost Of Revenue
2653000
Quarters > 2 > income Statement > gross Profit
4946000
Quarters > 2 > income Statement > operating Expenses
50381000
Quarters > 2 > income Statement > operating Income
-45435000
Quarters > 2 > income Statement > interest Expense
2150000
Quarters > 2 > income Statement > pretax Income
-47398000
Quarters > 2 > income Statement > net Income
-56569000
Quarters > 2 > income Statement > eps
-0.48826241966659467
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
115857780
Quarters > 2 > income Statement > income Tax Expense
9171000
Quarters > 2 > income Statement > EBITDA
-44202000
Quarters > 2 > income Statement > operating Margin
-597.9076194236084
Quarters > 2 > income Statement > total Other Income Expense Net
-1963000
Quarters > 2 > balance Sheet > cash
82411000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
62436000
Quarters > 2 > balance Sheet > inventories
3518000
Quarters > 2 > balance Sheet > total Current Assets
310175000
Quarters > 2 > balance Sheet > property Plant Equipment
2256000
Quarters > 2 > balance Sheet > total Assets
371066000
Quarters > 2 > balance Sheet > payables
40930000
Quarters > 2 > balance Sheet > short Term Debt
1723000
Quarters > 2 > balance Sheet > long Term Debt
265350000
Quarters > 2 > balance Sheet > total Liabilities
554536000
Quarters > 2 > balance Sheet > equity
-183470000
Quarters > 2 > cash Flow > net Income
-56569000
Quarters > 2 > cash Flow > depreciation
1046000
Quarters > 2 > cash Flow > change In Working Capital
10859000
Quarters > 2 > cash Flow > cash From Operations
-25826000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-17486000
Quarters > 2 > cash Flow > cash From Financing
-264000
Quarters > 2 > cash Flow > net Change In Cash
-43576000
Quarters > 2 > ratios > PE
-0.48826241966659467
Quarters > 2 > ratios > PB
-0.8524990625170329
Quarters > 2 > ratios > ROE
30.832833705782964
Quarters > 2 > ratios > ROA
-15.24499684692211
Quarters > 2 > ratios > FCF
-25826000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-3.3986050796157388
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
54144000
Quarters > 3 > income Statement > cost Of Revenue
33858000
Quarters > 3 > income Statement > gross Profit
20286000
Quarters > 3 > income Statement > operating Expenses
62532000
Quarters > 3 > income Statement > operating Income
-42246000
Quarters > 3 > income Statement > interest Expense
5346000
Quarters > 3 > income Statement > pretax Income
-50696000
Quarters > 3 > income Statement > net Income
-50696000
Quarters > 3 > income Statement > eps
-0.4392379844788427
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
115418069
Quarters > 3 > income Statement > income Tax Expense
-50696000
Quarters > 3 > income Statement > EBITDA
-44317000
Quarters > 3 > income Statement > operating Margin
-78.0252659574468
Quarters > 3 > income Statement > total Other Income Expense Net
-8450000
Quarters > 3 > balance Sheet > cash
125987000
Quarters > 3 > balance Sheet > short Term Investments
0
Quarters > 3 > balance Sheet > receivables
122334000
Quarters > 3 > balance Sheet > inventories
70094000
Quarters > 3 > balance Sheet > total Current Assets
341583000
Quarters > 3 > balance Sheet > property Plant Equipment
2837000
Quarters > 3 > balance Sheet > total Assets
448533000
Quarters > 3 > balance Sheet > payables
28456000
Quarters > 3 > balance Sheet > short Term Debt
1691000
Quarters > 3 > balance Sheet > long Term Debt
264927000
Quarters > 3 > balance Sheet > total Liabilities
580523000
Quarters > 3 > balance Sheet > equity
-131990000
Quarters > 3 > cash Flow > net Income
-50696000
Quarters > 3 > cash Flow > depreciation
5191999
Quarters > 3 > cash Flow > change In Working Capital
48196000
Quarters > 3 > cash Flow > cash From Operations
28608000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-542000
Quarters > 3 > cash Flow > cash From Financing
231000
Quarters > 3 > cash Flow > net Change In Cash
28297000
Quarters > 3 > ratios > PE
-0.4392379844788427
Quarters > 3 > ratios > PB
-1.1805015012500948
Quarters > 3 > ratios > ROE
38.40897037654368
Quarters > 3 > ratios > ROA
-11.302624333103696
Quarters > 3 > ratios > FCF
28608000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
0.5283687943262412
Quarters > 3 > health Score
50
Valuation > metrics > PE
2.4727
Valuation > metrics > PB
1.7876521464214918
Valuation > final Score
100
Valuation > verdict
37.6% Undervalued
Profitability > metrics > ROE
-40.480096611752906
Profitability > metrics > ROA
-7.708127691423241
Profitability > metrics > Net Margin
-3.0706939763201104
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
4.88464693417185
Risk > metrics > Interest Coverage
-19.06795698924731
Risk > final Score
-70
Risk > verdict
High
Liquidity > metrics > Current Ratio
17.274584020386747
Liquidity > metrics > Quick Ratio
17.197833907959826
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
100
Prev Profitabilities > 1
40
Prev Profitabilities > 2
40
Prev Risks > 0
-62
Prev Risks > 1
-55
Prev Risks > 2
-2
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:20:08.935Z
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACoherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving Average – Time to Sell? Defense World
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$5.6667
Analyst Picks
Strong Buy
3
Buy
1
Hold
3
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 59.43% of the total shares of Coherus BioSciences Inc
1.
BlackRock Inc(9.2403%)
since
2025/06/30
2.
Vanguard Group Inc(9.0947%)
since
2025/06/30
3.
TANG CAPITAL MANAGEMENT LLC(4.3857%)
since
2025/06/30
4.
Vanguard Total Stock Mkt Idx Inv(3.1313%)
since
2025/07/31
5.
Kohlberg Kravis Roberts & Co LP(2.6122%)
since
2025/06/30
6.
Geode Capital Management, LLC(2.3028%)
since
2025/06/30
7.
iShares Russell 2000 ETF(2.2216%)
since
2025/08/31
8.
CM Management, LLC(1.9359%)
since
2025/06/30
9.
State Street Corp(1.9088%)
since
2025/06/30
10.
CAM Group Holding A/S(1.6592%)
since
2025/06/30
11.
C WorldWide Healthcare Select 1A(1.6592%)
since
2025/07/31
12.
Vanguard Strategic Equity Inv(1.3629%)
since
2025/06/30
13.
Vanguard Explorer Inv(1.3531%)
since
2025/06/30
14.
Millennium Management LLC(1.1892%)
since
2025/06/30
15.
Vanguard Institutional Extnd Mkt Idx Tr(1.1348%)
since
2025/07/31
16.
Fidelity Small Cap Index(0.9324%)
since
2025/06/30
17.
BlackRock Advantage Small Cap Core Instl(0.8612%)
since
2025/07/31
18.
Citigroup Inc(0.8453%)
since
2025/06/30
19.
Charles Schwab Investment Management Inc(0.8444%)
since
2025/06/30
20.
Macquarie Group Ltd(0.7743%)
since
2025/06/30
21.
Macquarie Healthcare I(0.7743%)
since
2025/07/31
22.
Northern Trust Corp(0.7707%)
since
2025/06/30
23.
Rubric Capital Management LP(0.7466%)
since
2025/06/30
24.
Hudson Bay Capital Management LP(0.7184%)
since
2025/06/30
25.
Panagora Asset Management Inc(0.6834%)
since
2025/06/30
26.
AQR Capital Management LLC(0.6616%)
since
2025/06/30
27.
Tejara Capital Ltd(0.6012%)
since
2025/06/30
28.
iShares Russell 2000 Value ETF(0.5918%)
since
2025/08/31
29.
Fidelity Extended Market Index(0.5385%)
since
2025/07/31
30.
UBS Group AG(0.4943%)
since
2025/06/30
31.
Schwab US Small-Cap ETFâ„¢(0.4856%)
since
2025/08/30
32.
Vanguard Strategic Small-Cap Equity Inv(0.4803%)
since
2025/06/30
33.
Renaissance Technologies Corp(0.4499%)
since
2025/06/30
34.
Vanguard Russell 2000 ETF(0.4301%)
since
2025/07/31
35.
State St Russell Sm Cap® Indx SL Cl I(0.3356%)
since
2025/08/31
36.
Vanguard Health Care ETF(0.3096%)
since
2025/07/31
37.
Schwab Small Cap Index(0.248%)
since
2025/07/31
38.
NT R2000 Index Fund - NL(0.2301%)
since
2025/06/30
39.
iShares Russell 2000 Growth ETF(0.2246%)
since
2025/08/31
40.
Russell 2500â„¢ Index Fund F(0.2107%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.